Would you consider de-escalating abiraterone in a patient treated with ADT/abiraterone/prednisone for metastatic hormone sensitive prostate cancer who has had an excellent response with undetectable PSA and minimal side effects for over 2 years?   

Is there a concern regarding rarer side effect emergence (cardiac, bone, muscle, cognitive) of long term exposure to "maximal" androgen deprivation? Is there any expert or institutional experience with de-escalation to guide this further?   



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice